Any comments, Erik?
Press Release Source: Cell Therapeutics, Inc.
TRISENOX(R) Produces Durable Responses in Patients with Both High-Risk and Low-Risk Myelodysplasia
Sunday December 7, 7:00 am ET
Preliminary Results of Two Phase II Clinical Studies Reported at American Society of Hematology (ASH)
SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Preliminary data from two clinical trials of TRISENOX® (arsenic trioxide) injection in a total of 120 patients with myelodysplasia (MDS) were presented at the 45th Annual Meeting of the American Society of Hematology. MDS is a disease in which patients can become anemic and at risk for bleeding or infection as a result of the failure to produce red blood cells, platelets or infection fighting white blood cells. High risk MDS patients are also at risk of progressing to acute leukemia, which is often rapidly fatal. TRISENOX is marketed by Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC - News) for patients with relapsed or refractory acute promyelocytic leukemia.
Following treatment with TRISENOX, 28 of 120 patients (23 percent) with sufficient data for evaluation, in the two single-agent studies, including 14 high-risk (HR) and 14 low-risk (LR) patients, experienced a major or minor hematologic response (as defined by International Working Group). Responses were observed in each of the cell lineages and were seen after about eight to 24 weeks of TRISENOX therapy. In addition, TRISENOX treatment led to transfusion independence in 12 patients and a decrease of 50 percent or more in transfusion requirements for an additional five patients. Responses to TRISENOX were durable, lasting from just under eight weeks up to 46 weeks, with a median duration of approximately 15 weeks. |
